PHILADELPHIA, March 23, 2015 /PRNewswire/ -- The Intellectual Property and Science business of Thomson Reuters, the world’s leader in intelligent information for businesses and professionals, today released the 2015 edition of its annual Drugs to Watch report. The study reveals a significant increase in the number of expected blockbusters from three drugs in 2014 to eleven in 2015. Three of the new drugs are expected to reach more than $3 billion in sales by 2019. Thomson Reuters analysts utilized Cortellis™ Competitive Intelligence—the pharmaceutical industry’s leading source for drug pipeline, deals, patents, and company content—to forecast the new-to-market drugs expected to lead the pack in sales and potentially emerge as blockbusters (earning $ 1 billion+) by 2019.
The analysis spotlights the following 11 potential blockbusters, ranked by highest sales forecasts:
| Drugs to Watch | Company | Therapy Area | 2019 Sales Forecast in U.S. $ billions) |
| Opdivo (nivolumab) | Bristol-Myers Squibb | Melanoma | 5.684 |
| Praluent (alirocumab) | Regeneron Pharmaceuticals and Sanofi | Hypercholesterolemia | 4.414 |
| LCZ-696 (sacubitril and valsartan) | Novartis | chronic heart failure | 3.731 |
| Ibrance (palbociclib) | Pfizer | breast cancer | 2.756 |
| lumacaftor plus ivacaftor | Vertex Pharmaceuticals | cystic fibrosis | 2.737 |
| Viekira Pak (veruprevir, ritonavir, ombitsvir and dasabuvir) | AbbVie | hepatitis C | 2.500 |
| evolocumab | Amgen and Astellas Pharma | hypercholesterolemia/ hypherlipidemia | 1.862 |
| Gardasil 9 | Merck & Co. | HPV Vaccine | 1.637 |
| brexpiprazole | Otsuka Pharmaceutical and Lundbeck | schizophrenia and depression | 1.353 |
| Toujeo (new-formulation insulin glargine) | Sanofi | Diabetes | 1.265 |
| Cosentyx (secukinumab) | Novartis | psoriasis and psoriatic arthritis | 1.082 |
“This year’s forecast identifies a substantial increase in the number of predicted blockbusters, inviting discussion around the current status of the blockbuster model,” said Wendy Hamilton, global head of Life Sciences at Thomson Reuters. “As the pharmaceutical industry navigates constantly evolving revenue streams, this report serves as a valuable resource for identifying the therapies with the strongest sales potential.”
To learn more about the year’s most promising treatments, view 2015 Drugs to Watch. Learn more about Cortellis for Competitive Intelligence.
Thomson Reuters
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world’s most trusted news organization. For more information, go to www.thomsonreuters.com.
Jen Breen
+1 215 823 1791
Jennifer.breen@thomsonreuters.com
Molly Malone
+1 215 823 3702
molly.malone@thomsonreuters.com
Hey, check out all the research scientist jobs. Post your resume today!
